Magnetic Resonance - Technology Information Portal Welcome to MRI Technology
Info
  Sheets

Out-
      side
 



 
 't2' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 't2' found in 8 terms [] and 150 definitions []
previous     86 - 90 (of 158)     next
Result Pages : [1 2]  [3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... ]
Searchterm 't2' was also found in the following services: 
spacer
News  (28)  Resources  (5)  Forum  (66)  
 
C-SCAN™InfoSheet: - Devices -
Intro, 
Types of Magnets, 
Overview, 
etc.MRI Resource Directory:
 - Devices -
 
www.gehealthcare.com/usen/mr/cscan/index.html Manufactured by Esaote S.p.A.; compact in-office MRI system, fits in a 90 ft2 (8.4 m2) space and requires no shielding or special power. This low field MRI magnet is optimized for orthopedic use and imaging of the extremities.
The C-SCAN™ is developed from the ARTOSCAN™ - M with a new computer platform, and is also known as Artoscan C.
Esaote North America and Hologic Inc. are the U.S. distributors of this MRI device.
Device Information and Specification
CLINICAL APPLICATION
Dedicated extremity
CONFIGURATION
Closed
Linear and dual phased array, knee, ankle, wrist (6 total) coils
PULSE SEQUENCES
SE, GE, IR, STIR, FSE, 3D CE, GE-STIR, 3D GE, ME, TME, HSE
IMAGING MODES
Single, multislice, volume study, fast scan, multi slab
TR
12 - 5,000 msec
TE
5 - 220 msec
SINGLE SLICE
0.8 sec/image
MULTISLICE
0.8 sec/image
FOV
10 - 20 cm
2D: 2 mm - 10 mm;
3D: 0.6 mm - 10 mm
512 x 512
MEASURING MATRIX
256 x 256 maximum
PIXEL INTENSITY
4,096 gray lvls, 256 lvls in 3D
MAGNET TYPE
Permanent
BORE DIAMETER
or W x H
33.6 x 16 cm
MAGNET WEIGHT
960 kg
H*W*D
124 x 76 x 60 cm
POWER REQUIREMENTS
100/110/200/220/230/240
STRENGTH
10 mT/m
5-GAUSS FRINGE FIELD, radial/axial
28 cm/60 cm
Passive
spacer
MRI Resources 
Homepages - NMR - Implant and Prosthesis pool - General - Pathology - Distributors
 
Carr Purcell Meiboom Gill SequenceInfoSheet: - Sequences - 
Intro, 
Overview, 
Types of, 
etc.MRI Resource Directory:
 - Sequences -
 
(CPMG) This type of spin echo pulse sequence consisting of a 90° radio frequency pulse followed by an echo train induced by successive 180° pulses and is useful for measuring T2 weighted images. It is a modification of the Carr-Purcell RF pulse sequence, with 90° phase shift in the rotating frame of reference between the 90° pulse and the subsequent 180° pulses in order to reduce accumulating effects of imperfections in the 180° pulses. Suppression of effects of pulse error accumulation can alternatively be achieved by switching phases of the 180° pulses by 180°.
 
Images, Movies, Sliders:
 MRI - Anatomic Imaging of the Ankle 1  Open this link in a new window
    
SlidersSliders Overview

 Anatomic MRI of the Neck  Open this link in a new window
    
SlidersSliders Overview

 
spacer

• View the DATABASE results for 'Carr Purcell Meiboom Gill Sequence' (2).Open this link in a new window

 
Further Reading:
  Basics:
Fast Spin Echo(.pdf)
Tuesday, 24 January 2006   by www.81bones.net    
Magnetic resonance imaging
   by www.scholarpedia.org    
  News & More:
Spin echoes, CPMG and T2 relaxation - Introductory NMR & MRI from Magritek
2013   by www.azom.com    
MRI Resources 
DICOM - Implant and Prosthesis pool - Jobs pool - Crystallography - Collections - RIS
 
Carr Purcell SequenceInfoSheet: - Sequences - 
Intro, 
Overview, 
Types of, 
etc.MRI Resource Directory:
 - Sequences -
 
(CPS) Sequence of a 90° RF pulse followed by repeated 180° RF pulses to produce a train of spin echoes; is useful for measuring T2.
spacer
 
Further Reading:
  Basics:
Spin echoes, CPMG and T2 relaxation - Introductory NMR & MRI from Magritek
2013   by www.azom.com    
Searchterm 't2' was also found in the following services: 
spacer
News  (28)  Resources  (5)  Forum  (66)  
 
Clariscan™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
An iron-based contrast agent with large molecular size, which prevents diffusion into body tissues and will be developed for MR imaging of the liver (taken up by macrophages), tumor microvasculature and microvessel permeability. The blood half live of the particles with 11-20 nm diameter is 3-4 hours.
At this time the development of Clariscan™ is discontinued.

See also NC100150 Injection and Ultrasmall Superparamagnetic Iron Oxide.
Drug Information and Specification
NAME OF COMPOUND
Feruglose, PEG-feron, USPIO, NC100150
DEVELOPER
CENTRAL MOIETY
Fe
CONTRAST EFFECT
T2, Predominantly negative enhancement
R1=20, R2=35, B0=0.5T
PHARMACOKINETIC
Intravascular
CONCENTRATION
29.8 mg Fe/mL
PREPARATION
Suspend in an isotonic glucose solution
INDICATION
Cardiovascular
DEVELOPMENT STAGE
?
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
spacer

• View the DATABASE results for 'Clariscan™' (6).Open this link in a new window

 
Further Reading:
  News & More:
GE Healthcare expands MRI contrast media product range in Europe with launch of macrocyclic agent ClariscanTM
Wednesday, 1 March 2017   by www.businesswire.com    
GE Healthcare announces FDA approval of macrocyclic MRI contrast agent Clariscan
Monday, 4 November 2019   by www.itnonline.com    
MRI Resources 
MRI Physics - Societies - Resources - Mass Spectrometry - Bioinformatics - MRI Reimbursement
 
Combidex®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Combidex® is the brand name (same as Sinerem®) for an ultrasmall superparamagnetic iron oxide (USPIO) in the development pipeline to detect metastatic disease in lymph nodes. Metastatic lymph nodes show less uptake of this MRI contrast agent, which results in less signal decrease and allows the differentiation of normal lymph nodes from normal-sized, metastatic nodes. Combidex® has also potential to be used as a functional molecular imaging agent.
In March 2005, AMAG Pharmaceuticals Inc received an approvable letter from the U.S. Food and Drug Administration with respect to Combidex subject to certain conditions.
See also Ferumoxtran, Drug Development and Approval Process USA, Molecular Imaging and Classifications, Characteristics, etc.
Drug Information and Specification
NAME OF COMPOUND
Ferumoxtran, USPIO, AMI-227
CENTRAL MOIETY
Fe3+/Fe2+
CONTRAST EFFECT
T1, predominantly T2
r1=25, r2=160, B0=0.47T, r1=23.3, r2=48.9, B0=0.47T
PHARMACOKINETIC
Vascular, lymph v. hepatocyte (AG-USPIO)
DOSAGE
2.6 mg Fe/kg
PREPARATION
Suspend in an isotonic glucose solution
INDICATION
Lymph node, (MR angiography vascular, staging of RES-directed liver diseases)
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
spacer

• View the DATABASE results for 'Combidex®' (6).Open this link in a new window


• View the NEWS results for 'Combidex®' (1).Open this link in a new window.
 
Further Reading:
  Basics:
The demise of Combidex - Sinerem
Wednesday, 24 March 2010   by www.wellsphere.com    
  News & More:
Combidex, MRI, and identification of nodal metastases
Wednesday, 17 June 2009   by prostatecancerinfolink.net    
Superparamagnetic Iron Oxide–enhanced MR Imaging of Head and Neck Lymph Nodes1
MRI Resources 
Functional MRI - Fluorescence - Stimulator pool - DICOM - Pacemaker - Used and Refurbished MRI Equipment
 
previous      86 - 90 (of 158)     next
Result Pages : [1 2]  [3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... ]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?    



How AI will impact MRI :
only diagnostics 
saving time 
reducing cost 
makes planning obsolete 
reduce human knowledge 
not at all 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging • 
Copyright © 2003 - 2024 SoftWays. All rights reserved. [ 28 March 2024]
Terms of Use | Privacy Policy | Advertising
 [last update: 2024-02-26 03:41:00]